Quince Therapeutics, Inc. (QNCX) financial statements and ratios from SEC XBRL: revenue $1.24M (TTM), net margin -6750.7%, revenue growth 87.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $1.24M |
| Net Margin | -6750.7% |
| Revenue Growth (YoY) | 87.8% |
| EPS Growth (YoY) | 3520.6% |
| FCF Growth (YoY) | 63.7% |
| Price / Sales | 26.61 |
| FCF Yield | -139.0% |
| Altman Z-Score | 15.98 (safe) |
| Sector P/E (Healthcare) | 21.7 |
QNCX overview · QNCX earnings · QNCX KPIs · QNCX investor relations · QNCX ownership · QNCX peers · QNCX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.